Demis Hassabis: Isomorphic Labs Raises $5 Billion to Design Drugs With AI
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
Context
A $5 billion round co led by Greenoaks and Sequoia, with continued Alphabet backing, gives the AI drug design lab a much larger balance sheet to scale its engine and pipeline.
Demis Hassabis announced $5 billion in funding for Isomorphic Labs, the company he founded to design new medicines with AI. Isomorphic Labs posted its own announcement minutes earlier, saying the round was co led by Greenoaks and Sequoia Capital and linking to a company article on the Series C. That official post was under the 100,000 view floor used for lead posts, so it is in the links rather than the lead.
Deep dive
Demis Hassabis, founder of Isomorphic Labs, posted that the company has raised $5 billion to accelerate its mission to solve all disease. He said the lab is reimagining drug design from first principles with AI in order to cut the time and cost of finding new medicines.
Isomorphic Labs posted its own announcement a few minutes earlier. The official post said the $5 billion funding round was co led by Greenoaks and Sequoia Capital, and it pointed to a company article on the Series C. That official post had fewer than 100,000 views at scan time, under the floor used for lead posts, so the lead here is Hassabis, with the company post and article in the links.
According to the company's announcement, the round also included Andreessen Horowitz and several other new investors, plus continued significant investment from Alphabet. Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participated. The company said it is scaling its proprietary drug design engine, which it calls IsoDDE, and a pipeline of therapeutic candidates designed with AI.
The raise is one of the largest disclosed funding rounds for an AI drug design company. Hassabis is also the CEO of Google DeepMind, and Isomorphic grew out of that research. The announcement does not disclose a valuation or a precise use of proceeds beyond scaling the engine and the pipeline.
What to expect next
Watch for the first clinical candidates from the IsoDDE engine and for any detail on valuation, ownership, or how Alphabet's continued backing is structured. Rivals in AI drug design will be measured against a lab that now has a $5 billion war chest. Investors will also ask how quickly the new capital turns into trials, and whether later disclosures add partners, indications, or a timeline the announcement itself did not include.
